Journal of Medicinal Chemistry · 2012 · 71 citations · 34 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationMolecular VirologyAntiviral PharmacologyEnzyme InhibitionNucleic Acid Drug DesignPotency OptimizationViral HepatitisAntiviral Drug DesignAntiviral Structure-activity RelationshipsRna Helicase ActivityViral Helicase Inhibitors
A screen for hepatitis C virus (HCV) NS3 helicase inhibitors revealed that the commercial dye thioflavine S was the most potent inhibitor of NS3-catalyzed DNA and RNA unwinding in the 827-compound National Cancer Institute Mechanistic Set. Thioflavine S and the related dye primuline were separated here into their pure components, all of which were oligomers of substituted benzothiazoles. The most potent compound (P4), a benzothiazole tetramer, inhibited unwinding >50% at 2 ± 1 μM, inhibited the subgenomic HCV replicon at 10 μM, and was not toxic at 100 μM. Because P4 also interacted with DNA, more specific analogues were synthesized from the abundant dimeric component of primuline. Some of the 32 analogues prepared retained ability to inhibit HCV helicase but did not appear to interact with DNA. The most potent of these specific helicase inhibitors (compound 17) was active against the replicon and inhibited the helicase more than 50% at 2.6 ± 1 μM.
34
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Volker Lohmann, Frank Körner, Jan Oliver Koch et al. · Science · 1999 · 2.8K citations
An improved assay for nanomole amounts of inorganic phosphate
Peter A. Lanzetta, Lawrence J. Alvarez, Peter S. Reinach et al. · Analytical Biochemistry · 1979 · 2.2K citations
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon, Stuart C. Gordon, Eric Lawitz et al. · New England Journal of Medicine · 2011 · 1.6K citations · Full text
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem, Pietro Andreoné, Stanislas Pol et al. · New England Journal of Medicine · 2011 · 1.5K citations · Full text